Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucitanib in Advanced Cancer with Pathway Aberrations
NCT02747797Phase 2Withdrawn
- Start
- Apr 2017
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lucitanib in cancer. Planned start Apr 2017; status: withdrawn.
02
Drugs
lucitanib
03
Conditions
cancer
Beyond the preview
Go deeper on NCT02747797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02747797.